Corporate Satellite Workshops

The THSNA satellite symposium and product theater opportunities allow participating companies to maximize their visibility and impact at the Thrombosis and Hemostasis Summit of North America, as well as to directly host educational sessions.

These workshops are provided over meals (breakfast, lunch or dinner) and many offer continuing educational credits.

Enrollment for these workshops is open to all THSNA attendees and additional details will be posted here as they become available.

Thursday, April 14th


LUNCH SESSIONS

A New Era in Treating Hemophilia A and B: Long Acting Coagulation Factors May Improve Patient Outcome

Thursday, April , 14
12:15 PM - 1:45 PM
Ballroom 1 & 2

The recent introduction of new bioengineered Factor VIII and Factor IX replacement therapies with longer half-lives are expected to have profound implications on prophylaxis treatment regimens. The decreased frequency of infusions with these bioengineered therapies is expected to facilitate individualized treatment plans that will incorporate patient-specific targeted trough levels, reducing risk of breakthrough bleeds. Prophylaxis can protect against joint disease and allow a person with hemophilia to live a normal life with an average life expectancy – but the key to its effectiveness is early implementation and good adherence.  This educational activity will review the principles of pharmacokinetic-based factor replacement therapy, including its potential advantages and disadvantages as prophylaxis versus on-demand therapy. Because adherence is the cornerstone of effective prophylaxis, effective methods to measure and increase adherence—that can be practically implemented in a busy clinical setting – will be discussed.

This activity will be approved for 1.5 AMA PRA Category 1 Credits.

Supported by an unrestricted educational grant from Biogen


To register please go to: http://hemoa-b.eventbrite.com


Improving Outcomes for Patients with Hemophilia A: Evaluating Longer-Acting Treatment Options

Thursday, April , 14
12:15 PM - 1:45 PM
Ballroom 9 & 10

The Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation has recommended that prophylaxis for hemophilia A be implemented early, before frequent bleeds. The recent introduction of new bioengineered FVIII replacement therapies with longer half-lives are expected to have profound implications on prophylaxis treatment regimens, which have been notoriously associated with poor adherence. The decreased frequency of infusions with the newer products is expected to facilitate individualized therapies that will incorporate patient-specific targeted trough levels, reducing risk of breakthrough bleeds. Without specific guidelines on the use of these new treatments and their role relative to more established agents, however, clinicians need to understand the clinical implications of joint pain/damage and the emerging research surrounding newly available treatment regimens. This educational program will compare and contrast Fc fusion therapies with PEGylated therapies for prophylaxis treatment in hemophilia A. For each class of products, the faculty will review the technologies involved, available efficacy data, and information on toxicity and inhibitor formation. A discussion of which patients are appropriate for each type of therapy will also be included.

This activity will be approved for 1.5 AMA PRA Category 1 Credits.

 

Supported by an unrestricted educational grant from Baxalta US Inc

 

To register please go to: http://www.mycmesite.com/hemoA




DINNER SESSION

KOVALTRY® Antihemophilic Factor (Recombinant):
A Newly Approved Treatment Option

Thursday, April , 14
6:45 PM - 8:30 PM
Ballroom 1 & 2

Program Overview

This satellite symposium provides an overview of KOVALTRY® Antihemophilic Factor (Recombinant), a newly approved treatment option. Presentations and discussion will include the approved indications and important safety information of KOVALTRY, as well as other key prescribing information.  Pivotal clinical trial results from the LEOPOLD programs that support the indications and safety of KOVALTRY, will also be presented.

MEETING CHAIR

Victor Blanchette, MD, MA, MB, MRCS, LRCP, DCH, MRCP, FRCP(C), FRCP
The Hospital for Sick Children
Toronto, Ontario, Canada

FACULTY

Sanjay Ahuja, MD, MSc
University Hospitals
Rainbow Babies and Children’s Hospital
Cleveland, Ohio

Miguel A. Escobar, MD
University of Texas Health Science Center
MD Anderson Cancer Center
Houston, Texas

Prasad Mathew, MD, FAAP
University of New Mexico
Vice President, Global Medical Affairs, Bayer
Whippany, New Jersey

To register for this program:
Register quickly and easily online at http://www.regonline.com/BayerTHSNA

©2016 Bayer. All rights reserved.
KOVALTRY is a registered trademark of Bayer. Printed in the USA. March 2016. PP-675-US-0392


Friday, April 15th


BREAKFAST SESSION

Thrombosis: AFib & DVT/PE  An Exploration in Risk Reduction

Friday, April , 15
6:45 AM - 7:45 AM
Ballroom 1 & 2

Hosted by Janssen Pharmaceuticals, Inc.

Program Speaker:
Samuel Berkman, MD
Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Description:
This lecture will discuss treatment options for patients with deep vein thrombosis and pulmonary embolism, and how they can reduce the risk of recurrent thrombotic events. It will also present options for reducing the risk of stroke in patients with nonvalvular atrial fibrillation

Non-CME


LUNCH SESSIONS

Turning Challenges into Opportunities: Preparing for the Future of Hemophilia Care

Friday April , 15
12:15 PM - 1:45 PM
Ballroom 1 & 2

Hosted by Biogen

Today, more patients with hemophilia are living longer and healthier lives. This means greater complexities in managing the care of patients with hemophilia, but also the opportunity to help elevate the standard of care. Biogen is pleased to bring together an expert panel to discuss these issues in Turning Challenges into Opportunities: Preparing for the Future of Hemophilia Care on Friday, April 15th from 12:15 PM-1:45 PM. This symposium will highlight educational topics related to long-term outcomes, including prevention of joint damage and clinical approaches to help improve clinician-to-patient dialogue regarding adherence.  The panel discussion will be followed by a Q&A session. Lunch will be served during this event. To learn more, contact your Biogen representative or visit the Biogen booth in the exhibit hall at THSNA.


CSL Behring’s Breakthrough for Hemophilia B: Making a Long-Lasting Impression

Friday, April , 15
12:15 PM - 1:45 PM
Ballroom 9 & 10

Hosted by CSL Behring

Are you involved in hemophilia B treatment or research? You can’t miss this one! Come learn how and why CSL Behring’s extended half-life recombinant factor IX albumin fusion protein (rIX-FP) is poised to revolutionize the treatment of hemophilia B. Participate in this live panel of expert faculty to discover why rIX-FP will make a long-lasting impression on the hemophilia B community. This session will shed light on the unique molecular characteristics of rIX-FP and how they enable its long-acting mechanism of action. It will also address real-world experience with rIX-FP through Phase 3 clinical trials with a particular emphasis on health outcomes. The session will conclude with a discussion of future prophylaxis use in hemophilia B followed by Q&A.

RSVP:

Please click on the link below to inform us if you will be attending THSNA and would like to provide a courtesy RSVP for this exciting meeting. Lunch will be provided. www.cslbehringlunchsymposiumrsvp.com


DINNER SESSIONS

Diagnosis and Drug Monitoring in Bleeding Disorders: 2016 and Beyond

This educational symposium will be jointly provided by American Academy of CME, Inc. and E&S MedEd Group, Inc. This activity is supported by an educational grant from Novo Nordisk Inc.

Friday, April, 15
6:45 PM - 8:30 PM
Ballroom 1 & 2

The challenges in diagnosing and monitoring bleeding disorders lie in the sensitivity of the tests, the complicated algorithms for investigating and interpreting results, the potential for assay discrepancy and inaccuracy, and intra- and inter-laboratory variability. Predicting and monitoring patient response to factor replacement products is equally challenging, and traditional diagnostic assays do not always provide adequate information regarding the hemostatic activity of these agents. All of these issues increase the risk of misdiagnosis or suboptimal management. This 1.5 hour activity will provide an overview of standard and global assays to help multidisciplinary care team gain a broader understanding of the different assay types, assay components, reagents and instruments. The faculty will use case scenarios to outline the benefits and limitations of the different assays and offer insights on how to prevent errors and improve diagnostic accuracy. Additionally, the expert presenters will describe strategies for hemostatic monitoring of novel factor therapies and the implications of assay results for patients and their families.

CME/CNE Credits Available


Tackling Hemophilia’s Greatest Challenge: Inhibitors and the Role of FVIII Therapy

Friday, April, 15
6:45 PM - 8:30 PM
Ballroom 9 & 10

Hosted by Octapharma USA

An interactive dinner symposium and expert panel discussion on inhibitor formation in patients with Hemophilia A and the role of FVIII therapy in meeting this critical challenge.

Moderator:

Mindy Simpson, MD
Pediatric Hematology/Oncology
Rush Children’s Hospital and Rush University Cancer Center
Chicago, IL

Speakers:

Stacey Croteau, MD
Pediatric Hematology/Oncology
Boston Children’s Hospital / Dana-Farber Cancer Institute
Boston, MA

Guido Kohla, PhD.
Director of Molecular Biochemistry
Octapharma Biopharmaceuticals GmbH
Berlin, Germany

Joana Duran, DrNP
Director, Hematology
Scientific & Medical Affairs, Octapharma USA
Hoboken, NJ